Earnings summaries and quarterly performance for Editas Medicine.
Executive leadership at Editas Medicine.
Board of directors at Editas Medicine.
Research analysts who have asked questions during Editas Medicine earnings calls.
DG
Dae Gon Ha
Stifel
3 questions for EDIT
Also covers: ABEO, BEAM, CRBP +10 more
Jack Allen
Robert W. Baird & Co.
3 questions for EDIT
Also covers: ALLO, BLUE, CLLS +6 more
PN
Philip Nadeau
TD Cowen
3 questions for EDIT
Also covers: ADVM, APLS, ATRA +13 more
YZ
Yanan Zhu
Wells Fargo Securities
3 questions for EDIT
Also covers: ADAP, AFMD, ARCT +13 more
HW
Huidong Wang
Barclays
2 questions for EDIT
Also covers: ALNY, BCRX, BEAM +15 more
LI
Luca Issi
RBC Capital Markets
2 questions for EDIT
Also covers: ADVM, ALLO, ALNY +12 more
LM
Lut Ming Cheng
JPMorgan Chase & Co.
2 questions for EDIT
Also covers: ALLO, CHRS, NTLA +3 more
BC
Brian Cheng
JPMorgan Chase & Co.
1 question for EDIT
Also covers: ALLO, CHRS, IMVT +6 more
Cheng Li
Oppenheimer & Co. Inc.
1 question for EDIT
Also covers: EXEL, INO, NKTR +3 more
ES
Eric Schmidt
Cantor Fitzgerald & Co.
1 question for EDIT
Also covers: ADCT, AGIO, BIIB +9 more
Gena Wang
Barclays
1 question for EDIT
Also covers: ALNY, BCRX, BLUE +12 more
GH
Greg Harrison
RBC Capital Markets
1 question for EDIT
Also covers: ADCT, APLS, BBIO +3 more
Jay Olson
Oppenheimer & Co. Inc.
1 question for EDIT
Also covers: ACAD, AMGN, BIIB +22 more
Jingming Chen
Evercore ISI
1 question for EDIT
Also covers: IPHA
JL
Joon Lee
Truist Securities
1 question for EDIT
Also covers: ADVM, AXSM, CNM +14 more
J[
Julien [on for Liisa Bayko]
Evercore ISI
1 question for EDIT
MK
Mary Kate Davis
Bank of America
1 question for EDIT
Also covers: ARWR
Mehdi Goudarzi
Truist Securities
1 question for EDIT
Also covers: ARGX, NTLA, RARE +1 more
MB
Mia Bongiorno
Morgan Stanley
1 question for EDIT
NE
Nicholas Econom
Raymond James
1 question for EDIT
Also covers: APLS, WVE
Samantha Semenkow
Citigroup Inc.
1 question for EDIT
Also covers: ALLO, ARGX, BEAM +7 more
SS
Steven Seedhouse
Raymond James
1 question for EDIT
Also covers: APLS, BCRX, GLMD +2 more
Recent press releases and 8-K filings for EDIT.
Editas Medicine Details LDLR Program and Clinical Development Timeline
EDIT
New Projects/Investments
Guidance Update
- Editas Medicine is advancing a CRISPR editing strategy focused on upregulating proteins, with its lead program targeting LDLR for hypercholesterolemia.
- Preclinical data for the LDLR program showed a 90% reduction in LDL cholesterol in non-human primates with 10%-40% allelic editing, and durability was observed in murine models.
- The company aims to file an IND or CTA in mid-2026 and achieve human Proof of Concept by the end of 2026, initially focusing on heterozygous familial hypercholesterolemia patients.
- Editas Medicine's cash runway extends to Q3 2027, supporting the program through these initial clinical milestones.
Dec 2, 2025, 2:10 PM
Editas Medicine Provides Update on LDLR Program and Clinical Timelines
EDIT
New Projects/Investments
Guidance Update
- Editas Medicine is focusing its CRISPR editing efforts on upregulating the LDLR protein to treat hypercholesterolemia, aiming to deliver high-potency, low-cost therapies.
- Preclinical studies in non-human primates demonstrated a 6x increase in the LDL receptor and an unprecedented 90% reduction in LDL cholesterol, significantly surpassing the efficacy of current treatments like PCSK9s (60% reduction) and statins (40% reduction).
- The company anticipates filing an IND or CTA in mid-2026 and expects to achieve human proof-of-concept data by the end of 2026 for heterozygous familial hypercholesterolemia patients.
- Editas Medicine's cash runway extends to Q3 2027, providing sufficient financial resources to advance the LDLR program through its initial clinical milestones.
Dec 2, 2025, 2:10 PM
Editas outlines LDLR program strategy and preclinical data
EDIT
New Projects/Investments
Guidance Update
- Editas is focusing on its LDLR program, a CRISPR editing therapy aimed at upregulating the LDL receptor to reduce low-density lipoprotein cholesterol.
- Preclinical data in non-human primates showed an at least 6x increase in LDL receptor, resulting in a 90% reduction in cholesterol, an unprecedented level of reduction.
- The company plans to file an Investigational New Drug (IND) or Clinical Trial Application (CTA) in mid-2026, with human proof-of-concept (POC) data expected by the end of 2026.
- The initial patient population for the first-in-human trials will be heterozygous familial hypercholesterolemia (HeFH) patients.
- Editas's cash runway is projected to extend to Q3 2027, providing sufficient funding through these preliminary readouts.
Dec 2, 2025, 2:10 PM
Editas Medicine Announces Q3 2025 Results and EDIT-401 Program Updates
EDIT
Earnings
Guidance Update
New Projects/Investments
- For the third quarter of 2025, Editas Medicine reported a net loss of $25.1 million ($0.28 per share) and collaboration and other research and development revenues of $7.5 million.
- The Company has extended its cash runway into the third quarter of 2027, partly due to $17.8 million in gross equity proceeds from its at-the-market (ATM) facility during Q3 2025.
- Preclinical data for its lead in vivo development candidate, EDIT-401, demonstrated over 90% LDL-C reduction in non-human primates.
- Editas Medicine is on track to submit an investigational new drug (IND) or clinical trial application (CTA) for EDIT-401 by mid-2026 and aims to achieve initial human proof-of-concept data by year-end 2026.
Nov 10, 2025, 12:06 PM
Chardan's 9th Annual Genetic Medicines Conference Highlights Advancements in Gene Editing Therapies
EDIT
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- The conference emphasized the coexistence and evolution of diverse gene editing technologies, with a focus on product profile and directing tools to their most effective applications.
- Delivery mechanisms are critical, with LNPs being a leading in vivo method, though requiring optimization. Non-viral approaches are highlighted for their potential to achieve lower cost of goods and enhance commercial viability.
- Companies reported strong clinical progress and commercial viability for one-time gene editing therapies, exemplified by Editas Medicine's EDIT-401 achieving a 90% reduction in LDL C and targeting human Proof-of-Concept by 2026.
- Several participants provided pipeline updates, including Yultech Therapeutics with 4-5 programs in the clinic and a Phase 3 program starting early next year (2026) , and Gen Edit Bio having dosed 4 patients in an IIT for TGFBI mutant corneal dystrophy with an FDA IND filing planned by year-end (2025).
Oct 21, 2025, 12:45 PM
Editas Provides Update on EDIT-401 LDLR Program and Strategic Focus
EDIT
New Projects/Investments
Guidance Update
- Editas is primarily focused on its EDIT-401 LDLR program, an in vivo gene editing therapy designed to achieve a 90% reduction in LDL-C.
- The company plans to file an Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026 and anticipates having human proof of concept data by the end of 2026.
- Editas emphasizes the differentiated efficacy of its upregulation strategy, which has shown a six-fold increase in LDL receptor levels in nonhuman primates, leading to a 90% LDL-C reduction, surpassing the 40-60% reduction seen with current standard-of-care treatments.
- The company has a cash runway that extends into Q2 2027, which is expected to fund the IND/CTA filing, human proof of concept, and further development.
- The initial target market for EDIT-401 is expected to be refractory heterozygous familial hypercholesterolemia patients, with potential for expansion into broader hypercholesterolemia populations as long-term safety is established.
Oct 14, 2025, 11:00 AM
Editas Outlines EDIT-401 Program Milestones and Cash Runway
EDIT
New Projects/Investments
Guidance Update
- Editas is an in vivo gene editing company primarily focused on its EDIT-401 LDLR program, which aims to achieve a 90% reduction in LDLC.
- The company plans to file an IND or CTA by mid-2026 and expects to have human proof-of-concept data by the end of 2026 for the EDIT-401 program.
- The EDIT-401 program is designed as a single-dose, durable therapy with a potentially superior efficacy and safety profile compared to current standards of care, utilizing lipid nanoparticles for cost-effectiveness and scalability.
- Editas has cash into Q2 2027, which is sufficient to fund the IND/CTA filing and human proof-of-concept for EDIT-401 and beyond.
- The company is also working on selecting a third tissue target to expand its platform, while its hematopoietic stem cell (HSC) program is being optimized for future development.
Oct 14, 2025, 11:00 AM
Editas Medicine Reports Positive Preclinical Data for EDIT-401
EDIT
New Projects/Investments
- Editas Medicine, Inc. reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental gene-editing therapy aimed at significantly reducing LDL-cholesterol (LDL-C).
- Preclinical studies demonstrated ≥90% mean LDL-C reduction in non-human primates within 48 hours of a single dose and in mouse models.
- The LDL-C reduction was maintained in mouse models in a three-month study, indicating a durable effect.
- The therapeutic strategy involves a CRISPR/Cas9 nuclease and dual gRNAs with LNP delivery to upregulate the LDL receptor (LDLR), resulting in a ≥6-fold mean increase in LDLR protein in the non-human primate liver.
Oct 9, 2025, 8:31 PM
Editas Medicine Reports Preclinical Proof-of-Concept Data for EDIT-401
EDIT
New Projects/Investments
- Editas Medicine reported in vivo preclinical proof-of-concept data for its experimental therapy, EDIT-401, at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress on October 9, 2025.
- EDIT-401 is a potential one-time therapy designed to significantly reduce LDL-cholesterol (LDL-C) through the upregulation of the LDL receptor (LDLR).
- Preclinical studies demonstrated robust efficacy, achieving ≥90% LDL-C reduction in non-human primates within 48 hours of a single dose, and a durable effect maintained in mouse models over a three-month study.
Oct 9, 2025, 3:01 PM
Editas Medicine Nominates Lead Gene Editing Candidate EDIT-401 and Updates Financial Position
EDIT
Product Launch
New Projects/Investments
Guidance Update
- Editas Medicine nominated EDIT-401 as its lead in vivo development candidate, an experimental gene editing medicine targeting hyperlipidemia.
- EDIT-401 achieved approximately 90% mean LDL cholesterol reduction with a single dose in non-human primate studies, significantly outperforming standard-of-care therapies.
- The company expects to achieve human proof-of-concept data by the end of 2026 and plans to submit an investigational new drug application by mid-2026.
- As of June 30, 2025, Editas Medicine reported $178.5 million in cash, cash equivalents, and marketable securities, providing an operational runway into the second quarter of 2027.
Sep 25, 2025, 1:15 PM
Quarterly earnings call transcripts for Editas Medicine.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more